These webinars are brought to you by the Access to COVID-19 Tools (ACT) Accelerator’s Country Readiness and Delivery (CRD) workstream, Project ECHO, Boost, TechNet-21, and the COVID-19 Vaccine Equity Project.
Answers to all questions asked during the webinar session and in the two Telegram channels have now been answered by the session presenters. The full Q&A has been consolidated into a single document that can be found here:
With now 25 million people vaccinated in UK, there is no sufficient capacity of GPs to receive calls from hundreds of thousands of people with adverse events, or for hospitalisation or in person medical attention. Don't you think there will be inevitable inconsistencies in thresholds of reporting by country?
In the case of death, who is the person eligible to apply [for the NFC Programme]? Is that decided ahead?
Do countries have enough capacity to analyse the adverse events? If not, does the WHO provide the technical support for that?
Is there a guide on advising patients who reported AEFIs over the telephone?
How can we attend to various unexpected adverse reactions to prevent fatalities among vaccinated recipients? In case there is any reaction after taking the vaccines, what medicine is the patient supposed to take?
How can we measure the PEG (polyethyleneglicol) tolerance related reaction due to the COVID-19 vaccination?
There are no replies made for this post yet.
Please login to post a reply
You will need to be logged in to be able to post a reply. Login using the form on the right or register an account if you are new here. Register Here »